明基醫 (4116.TW) 2025Q4 financial report shows revenue of 1.37B TWD, with a YoY growth rate of 4.23%. This figure indicates that 明基醫 (4116.TW)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of 明基醫 (4116.TW)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.